Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.

about

Does pasireotide directly modulate skeletal muscle metabolism?

P2860

Q48307756-6623AB30-6C0D-4BFE-93F4-ED7479532A79

P2860

Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.

Item

http://www.wikidata.org/entity/Q51170240

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effects of pasireotide (SOM230 ...... in rat skeletal muscle cells.

@en

Effects of pasireotide

@nl

type

Item

label

Effects of pasireotide (SOM230 ...... in rat skeletal muscle cells.

@en

Effects of pasireotide

@nl

prefLabel

Effects of pasireotide (SOM230 ...... in rat skeletal muscle cells.

@en

Effects of pasireotide

@nl

P1476

Effects of pasireotide (SOM230 ...... in rat skeletal muscle cells.

@en

P2093

Andrea Giustina

http://www.w3.org/2001/XMLSchema#string

Giovanni Tulipano

http://www.w3.org/2001/XMLSchema#string

Lara Faggi

http://www.w3.org/2001/XMLSchema#string

Maurizio Spinello

http://www.w3.org/2001/XMLSchema#string

P2860

Somatostatin and its receptor family

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.

Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes

Somatostatin receptors: from signaling to clinical practice.

Managing Cushing's disease: the state of the art.

Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.

Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.

Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes.

P2888

s12020-017-1235-3

P304

179-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-017-1235-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stefan Schulz

P577

2017-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28120181

http://www.w3.org/2001/XMLSchema#string

Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.

about

P2860

P2860

Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698